Advertisement

Current Pathobiology Reports

, Volume 1, Issue 1, pp 63–70 | Cite as

miRNA-Based Therapeutic Strategies

  • Masaharu Ishida
  • Florin M. SelaruEmail author
miRNA in Pathobiology (T Patel, Section Editor)

Abstract

Micro-RNAs (miRNAs) are short, non-coding RNA species, thought to act primarily through downregulation of target mRNA species with subsequent decrease in encoded proteins. Recent studies revealed that miRNAs play pivotal roles in physiology and disease, and therapeutic targeting has started being investigated. Generally, the upregulation of miRNAs is achieved through administration of synthetic miRNAs or administration of miRNA expressing vectors. The downregulation of miRNAs is achieved through administration of anti-sense nucleotides, often chemically modified to ensure stability and specificity. There are multiple potential limitations associated with the development and testing of miRNA-based therapeutics. These issues include, but are not limited to, off-target effect, avoidance from internal nucleases, and toxicity for miRNA therapy. In this review, we will discuss recent advances in miRNA based therapeutic strategies.

Keywords

MicroRNA Therapy Antagomir OncomiRNAs Cancer 

Introduction

MicroRNAs (miRNAs) are short (~22 nucleotides), single stranded, non-coding RNA species that were first reported to have a function in 1993 [1]. It is believed that miRNAs exert their function mainly through binding of 6–8 nucleotide sequences (miRNA seed) to complementary sequences in target messenger RNA (mRNA), resulting in transcript degradation or translation inhibition, with the net effect of decreasing target protein amount [2•]. While some miRNA species are transcribed independently, others originate in introns or exons of genes and are transcribed in concert with mRNA species [3]. The transcribed RNA (pri-miRNA) contains the mature miRNA sequence (guide strand) as well as the complementary sequence (passenger strand). Within the nucleus, the enzyme Drosha cuts the pri-miRNA to pre-miRNA [4], which is then transferred out of the nucleus by a carrier protein, Exportin-5 [5]. Within the cytoplasm, pre-miRNA is processed by the enzyme Dicer to 20-25 base mature miRNAs [6]. Mature miRNA is then incorporated into the RNA-induced silencing complex (RISC), and interacts with target messenger RNA species [7]. Following initial reports of miRNA function, a plethora of studies identified salient roles for miRNAs in regulating a variety of physiologic and pathologic states. As the mechanism and role of miRNAs in human disease is gradually unraveled, recent studies also started exploring the role of miRNAs as therapeutics.

miRNA-based Therapeutic Strategies: Design, Pitfalls and Challenges

The process of developing miRNA-based therapeutics is somewhat similar to conventional drug discovery and testing protocols. An overview of miRNA-based therapeutic strategies is shown in Fig. 1. From a historical perspective, the development of conventional drugs generally starts with large screening tests, without preexisting hypotheses regarding mechanism of action. In contrast, most efforts to date to select miRNAs as targets for therapy were based on prior knowledge regarding disease specific miRNA dysregulation [8]. Although hypothesis-free screening of miRNAs as therapeutics can hypothetically be employed, the strategies used so far are likely based on the fact that miRNAs are intrinsic regulatory molecules, with defined, physiological functions. For example, miRNA-34 was found to have tumor suppressive roles in a variety of human tumors, and later became the focus of miRNA-based therapeutics [9, 10]. Following identification of miRNA species dysregulated in cancer, the next step usually entails functional characterization of the candidate miRNA species in vitro and in vivo through gain or loss of function studies. Gain of function can be accomplished through introduction of synthetic miRNA (either transfection or viral transduction). Loss of function can be accomplished by employing complementary antisense oligonucleotides, usually modified chemically to ensure stability and specificity.
Fig. 1

Typical algorithm for identification and testing of miRNA species as therapeutics. The typical first step is identification of miRNA species that are differentially expressed between the diseased tissue of interest and normal tissue. Next, the miRNA is tested for function, as the screening alone cannot rule out that an miRNA is differentially expressed, but plays no etiologic role. Next, the miRNA species is optimized in terms of in vivo delivery, pharmacokinetics (PK), pharmacodynamics (PD), and absorption, distribution, metabolism, and excretion (ADME). Animal studies are then performed, followed by clinical trials

miRNA Mimic-based Therapeutics: Technology and Challenges

RNA molecules are anionic, hydrophilic and are generally not taken up by cells via passive effusion [11]. In addition, miRNAs may also be unstable in vivo due to rapid degradation by endogenous nucleases as well as rapid elimination through hepatic and renal metabolism and excretion [12]. One method to circumvent some of these limitations is local, rather than systemic, administration of RNA-based therapeutics [13]. Systemic administration is more challenging and efforts are underway to alter miRNA sequences through chemical modifications [12]. Atelocollagen coupling to miRNA molecules is such a modification, and offers several advantages: increased cellular uptake and nuclease resistance, without evoking interferon-based immune responses [14, 15]. miRNA can also be delivered as lipid-based nanoparticles [16•, 17]. Lipid nanoparticles can reduce the negative electrical charge of RNA nucleotides and promote their cellular uptake [18]. Another strategy for efficient systemic delivery of miRNA therapeutics is through viral vectors [19]. Adeno-associated virus vectors [20] or lentiviral vectors [21] can be used to transfer miRNAs to cells. Specificity of viral-mediated delivery continues to be a challenge, and current approaches employ viral serotypes demonstrated to more selectively transduce the cell type of interest, as well as using specific promoters [22•, 23].

miRNA Inhibitor-based Therapeutics: Technology and Challenges

To reduce endogenous miRNA levels, anti-sense oligonucleotides [24], called AMO (anti-miRNA antisense oligomer), also called antagomir [25], are usually employed. Various methods have been tested to render AMO constructs more stable in vivo and to ensure adequate tissue availability and specificity. For example, 2’-O-methyl (2′-OMe) modified RNA is chemically more stable than unmodified RNA, and more resistant to nucleases due to the methylated hydroxyl base [26, 27, 28]. Also, 2’-O-methoxyethyl (2′-MOE) phosphorothioate and 2′-fluoro/2′-methoxyethyl (2′-F/MOE) modifications have been employed to increase the efficiency of the synthetic oligonucleotide against the target miRNA [29, 30, 31, 32]. In addition, conjugation with cholesterol appears to improve activity of the nucleotide sequence [27, 33, 34]. Locked nucleic acid (LNA) is another method to modify antisense oligonucleotides, where the 2′ oxygen and 4′ carbon of the nucleotide are bridged with methylene and form a cyclic structure. Because LNA is locked by this bridge, it does not transition between conformations, in contrast to the naked nucleotide sequence. LNA is more resistant to the endogenous nucleases, has stronger affinity to the target nucleotide [35, 36], and displays lower toxicity [37]. Last, peptide nucleic acid (PNA) is an artificially synthesized polymer that has a peptide structure in the main chain and similarity to DNA and RNA [38]. Because it does not have an organophosphate moiety, these constructs bind to target nucleotide sequences more tightly than nucleotide/nucleotide binding. In addition, PNA appears to be relatively stable and can be administered systemically with relatively low toxicity [39].

miRNA Sponge and miRNA Masking: An Indirect Method to Reduce Endogenous miRNA Species

miRNA sponges and masking are relatively new strategies employed to downregulate miRNAs. MiRNA sponges contain multiple target sites complementary to a target miRNA that is deemed to be of potential therapeutic relevance [40, 41]. miRNA masking entails the design and administration of sequences complementary to a miRNA binding site in the 3′ UTR of the target mRNA. Through the competitive inhibition of the interaction between the miRNA and mRNA species, the miRNA mask reduces the activity of endogenous miRNA [42].

miRNA Off-target Effects

Decades of conventional drug discovery and design suggest that drug off-target effects are a salient aspect of the development process. Off-target effect challenges are applicable, to a certain extent, to developing miRNA-based therapeutics [43]. Small RNA species, of the miRNA as well as siRNA type, can bind not only to fully complementary nucleotide sequences, but also to similar sequences [44]. Off-target effects may cause unexpected consequences, sometimes completely negating the utility of a particular small RNA species as therapeutics. The probability of off-target effects can be predicted for small interfering (si) RNA [45, 46], however, the true magnitude of off-target effects cannot be fully known until in vivo studies are performed. Off-target studies with miRNAs are, in comparison with siRNA studies, not as well developed. In addition, although not proven on a large scale, we believe that miRNA species may escape the “off-target effects curse”, at least to a certain extent. The main advantage of miRNA species when compared to synthetic siRNA species is the fact that miRNAs are intrinsic molecules. If we hypothesize that their modus operandi is through effects of small amplitude exerted on multiple targets simultaneously, then, by definition, their effects cannot be considered off-target. While in vitro and some preliminary in vivo studies suggest that this hypothesis is true, further in vivo studies are clearly needed [47].

Specific miRNA-based Therapeutic Advances

Cancer

Dysregulated miRNA species have been reported to be involved in carcinogenesis, cancer progression, and drug resistance [48, 49]. Theoretically, miRNA species upregulated in cancer (oncomiRNAs) as well as downregulated in cancer (tumor suppressor miRNAs, or TSmiRNAs) can be targeted for miRNA based therapeutics. Table 1 contains a list of the more studied oncomiRNAs as well as TSmiRNAs.
Table 1

Representative oncomiRNA and TS miRNA species

Cancer

OncomiRNA

TSmiRNA

Breast cancer

mir-21 [9]

mir-34b [78]

Colorectal cancer

mir-211 [79]

mir-33a [80]

Gastric cancer

mir-192 [81], mir-215 [81]

mir-125a [82]

Glioma

mir-21 [83]

mir-34a [10]

Hepatocellular carcinoma

mir-21 [50]

mir-26a [22•]

Leukemia

mir-100 [84]

mir-33a [80]

Lung cancer

mir-31 [85]

mir-101 [86]

Ovarian cancer

mir-21 [87]

let-7 [88]

Pancreatic cancer

mir-21 [89]

mir-150 [90]

Prostate cancer

mir-32 [91]

mir-34a [92]

Therapeutic miRNA-21 Blockade in Cancer

miRNA-21, located in a coding gene, transmembrane protein 49, is one of the most studied miRNA species in human cancer. The collective knowledge from several studies indicates that miRNA-21 regulates a multitude of target genes, most of which are known to exert tumor suppressor effects. The targets of miRNA-21 include phosphatase and tensin homolog (PTEN), sprouty homolog 1 (SPRY1), B cell CLL/lymphoma 2 (BCL2), and others [50]. miRNA-21 was associated with a variety of cancers, including leukemia [51], lung [52], liver [50], stomach [53], pancreas [54], and brain [55]. Several in vitro as well as in vivo studies demonstrated that reducing miRNA-21 levels with anti-sense nucleotides results in delayed cancer growth in gastric cancer [53], gliomas [56] and other cancers.

Therapeutic miRNA-26 Upregulation in Hepatocellular Carcinoma

miRNA-26 was first implicated in liver cancers in a profiling study performed on a large cohort of human specimens [57]. Additional mRNA profiling also identified a possible involvement of miRNA-26 in nuclear factor Kappa B and Interleukin-6 pathways, further suggesting an etiologic role for this miRNA in liver cancer genesis or homeostasis. Building on prior data regarding the downregulation of miRNA-26a in liver cancers, another group investigated the usage of miRNA-26a as liver cancer therapeutics in vivo [22•]. This is the first study to successfully use adeno-associated viruses (AAVs) to deliver miRNA in vivo to a mouse model of hepatocellular carcinoma, and resurrected the interest in AAVs as delivery methods for miRNAs. This study, however, also raises an interesting point regarding organ and tissue specific expression of miRNAs. Specifically, miRNA-26 does not appear to be underexpressed in all human tumors, suggesting that miRNA expression is highly tissue-dependent. This finding advocates caution in using miRNAs for therapeutics, in particular if the specificity of tissue delivery is not finely tuned. For example, miRNA-26 was found to be up-regulated in glioblastoma and over-expression of miRNA-26 increases tumor growth and proliferation [58]. Although it is currently not known if upregulation of miRNA-26 in normal cells can, under certain conditions, promote de novo cancer genesis, these findings are of unquestionable concern. It is conceivable that liver-specific delivery of miRNA-26 may be possible, however, hepatocellular cancer cell, or hepatocyte-specific delivery may be significantly more difficult to accomplish. The need for hepatocyte-specific delivery was further suggested by a recent study, that found overexpression of miRNA-26a in human cholangiocarcinoma (CCA) [59]. These findings are more so concerning since the same study reported an etiologic role for miRNA-26 in CCA growth. These recent data raise a serious concern regarding miRNA-26 supplementation in hepatocellular cancers and further emphasize the need for tissue and cell type specific targeting of miRNA based therapies.

Therapeutic Let-7 Upregulation in Cancers

The Let-7 family is one of the first identified miRNAs, and it is highly conserved in a wide range of species, suggestive of its functional role [60]. Further studies identified a tumor suppressive role for this miRNA family in a variety of cancers [61, 62, 63]. Mechanistic studies found that Let-7 directly binds to the 3′UTR of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) resulting in its downregulation [64]. In addition, let-7 has been reported to downregulate other oncogenes, such as high-mobility group AT-hook 2 (HMGA2) and v-myc myelocytomatosis viral oncogene homolog (MYC) [64]. Gain of function studies demonstrated that induction of let-7 inhibits DNA replication and regulates apoptosis [64]. These data suggested that let-7 is an attractive miRNA for treatment for cancer. In vivo upregulation of let-7 in various cancers, such as prostate cancer [65], and lung cancer by nasal administration [66], by inducible vector [67], or exogenous delivery [23], induced decreased cell proliferation. Further studies are needed to accurately assess the utility of let-7 based miRNA therapeutics in vivo.

Hepatitis C infection

Therapeutic miRNA-122 Blockade in Hepatitis C

miRNA-122 is one of the most studied miRNAs as in vivo therapeutics. Several studies demonstrated that miRNA-122 plays a pivotal role in a variety of liver-centric physiologic and pathologic processes. In vivo antisense blockade of miRNA-122 in liver results in significantly decreased plasma cholesterol levels in mice, as well as in non-human primates [29, 35]. Interestingly, these studies also demonstrated that miRNA blockade in vivo can have an enduring effect [35]. Additional studies revealed yet another surprising role for miRNA-122 in Hepatitis C (HCV) infection. In vitro studies demonstrated that miRNA-122 expression is a requirement for HCV replication through direct binding to sites within the 5′UTR of HCV [68]. Following these results, Santaris Pharma introduced a locked nucleic acid (LNA) miRNA-122 antisense sequence and preliminary experiments in non-human primates demonstrated a significant reduction of HCV titer in the higher dose group [69•]. Also of note, the effect was maintained over several weeks while therapy was administered. In addition, there was no evidence of liver toxicity or HCV mutations. These preliminary results formed the basis of a recently concluded phase 2a study led by Santaris Pharma, published in abstract form at the 2011 Annual meeting of the American Association for the Study of Liver Diseases (AASLD). The authors reported that 4 of the 9 patients on the high dose of anti-miR-122 therapy had no detectable HCV titer 4 weeks after initiation of therapy.

These studies also shed some light onto other aspects of miRNA functioning. Interestingly, miR-122 binds to the 5′UTR of HCV, not to the typical 3′UTR location. In addition, miR-122 binding appears to stimulate, rather than inhibit the expression of HCV [68]. Another interesting observation stemmed from measuring and correlating miRNA-122 levels in serum of HCV patients with serum HCV titers [70]. Interestingly, there was no correlation between serum levels of HCV and miRNA-122. In other words, if the first step in identifying a miRNA that may inhibit HCV were a profiling study, miRNA-122 would not have been found. This study raises an important question: is the current protocol involving profiling human tissues to identify dysregulated miRNA species with the purpose of finding candidate miRNAs for therapeutics the best approach? Would a typical drug screening approach, where knowledge regarding miRNA levels in diseased tissue compared to normal tissue is irrelevant, work better?

A significant area of concern with further developing miRNA-122 blockade for human use stems from the observation that miRNA-122 has low levels of expression in HCC [71]. Down-regulation of miRNA-122 is observed in patients with HCC and over expression of miRNA-122 inhibits tumor proliferation in HCC cell lines [72]. Moreover, two recent studies demonstrated that miR-122 deletion in mice results in hepatosteatosis, fibrosis and HCC development [73, 74]. In our view, these seemingly contradictory results do not necessarily suggest the presence of off target effects, but they rather underline the paramount importance of tissue and temporal specific miRNA manipulation. In our opinion, these studies argue that miRNA-122 levels may play roles of vastly different magnitude on a variety of processes (growth, stemness, fibrosis, cancer development, Hepatitis C infection) dependent on cell type as well as on developmental stage.

Fibrosis

Therapeutic miRNA-21 Blockade in Heart Fibrosis and miRNA-21 Upregulation in Abdominal Aortic Aneurysms (AAA)

In response to injury, fibroblasts produce extracellular matrix as a normal, physiologic response. However, uncontrolled matrix production leads to fibrosis and to a variety of fibrosis-related complications, such as idiopathic pulmonary fibrosis, liver cirrhosis, scleroderma, bowel strictures or bone marrow failure. Transforming growth factor beta (TGF-b) is thought to be a central mediator of fibrosis, and miRNA-21 is a known modulator of TGF-b pathway. Several groups, therefore, studied the utility of miRNA-21 blockade in various fibrosis models. In a mouse model of lung fibrosis, reminiscent of human idiopathic pulmonary fibrosis, antisense blockade of miRNA-21 was shown to diminish the magnitude of the fibrotic process [75]. In a different study, miRNA-21 was found to be upregulated in activated fibroblasts of the failing heart, with a direct impact onto the extent of heart fibrosis [76•]. Based on these findings, an in vivo study of a mouse model of pressure-overload-induced heart disease found that administration of a miRNA-21 antisense construct reduces the extent of heart fibrosis and overall heart function [76•]. In sharp contrast, a different study in a mouse model of abdominal aortic aneurysm (AAA) found that miRNA-21 blockade increased the size of the AAA and conversely, miRNA-21 overexpression limited the expansion of AAA [21]. Although these findings are encouraging for the potential utility of miRNA-21 overexpression for patients with AAA, clear concerns exist regarding potential side effects from upregulating miRNA-21 in liver (where high levels are associated with HCC) or heart (where high levels are associated with increased fibrosis).

Lipid Metabolism

Therapeutic miRNA-33 Blockade

miRNA-33a and miRNA-33b are located within the intron of sterol regulatory element-binding proteins (SREBP) 2 and SREBP1, respectively. SREBPs are key genes for cholesterol synthesis and uptake. Interestingly miRNA-33a and miRNA-33b were also found to play a pivotal role in lipid metabolism, through interaction with adenosine triphosphate-binding cassette transporter A1 (ABCA1) and ABCG1, regulators of high density lipoprotein synthesis [77•]. Therefore, systemic antagonism of miRNA-33 is expected to improve lipid metabolism and reduce plaque formation in vessels. Mice on a western diet injected with LNA-antisense to miRNA-33 demonstrated an increased in plasma levels of high density lipoprotein (HDL) [77•]. Moreover, in vivo inhibition of miRNA-33 was found to have a reduction in atherosclerotic plaques size and lipid content, through raising ABCA1 levels in the liver, as well as in the plaque macrophages [32].

Spinal and Bulbar Muscular Atrophy (SBMA)

Therapeutic miRNA-196a Upregulation in SBMA

SBMA, also known as Kennedy–Alter–Sung disease, is an inherited neurodegenerative disorder that results in proximal muscle weakness, atrophy, contractions and bulbar involvement. So far, there are no curative treatments for SBMA. A recent study evaluated AAV-mediated delivery of miRNA-196a in a mouse model of SBMA [20]. CUGBP, Elav-like family member2 (CELF2) is known to bind to the mutated androgen receptor and stabilize it. miRNA-196a was found to be overexpressed in spinal cords of SBMA mice compared to controls, perhaps as a protective, albeit insufficient, mechanism. In addition, miRNA-196 binds to CELF2 and represses it, resulting in a lower amount of mutated androgen receptor, with amelioration of SBMA. An AAV vector expressing miRNA-196a delivered in vivo to SBMA mice induced clinical improvement and represents an exciting new therapeutic venue to be explored in SBMA clinical trials.

Conclusion

miRNA-based therapeutics is an emerging field showing significant promise. Studies in mice, non-human primates and early trials in humans clearly demonstrate that there is potential for developing miRNAs into valuable therapeutics. There are, however, multiple areas of concern that deserve further investigation. For example, it is not entirely clear if miRNAs should be viewed similarly to siRNAs or chemical compounds in terms of off-target effects. miRNAs appear to be built-in regulatory molecules, designed to exert global modulation through moderate effects on a multitude of targets. Therefore, development of miRNAs into therapeutics may be less prone to true off-target effects. Nonetheless, while true off target effects could be rare, the same cannot be stated regarding side effects. There are several examples (miRNA-21, miRNA-122, and others) where downregulation in a diseased tissue appears beneficial, but data from a different tissue or disease indicate severe potential side effects of decreasing same miRNA levels, probably in particular if chronic treatment is necessary. Other areas of further research include efficient in vivo delivery. In vivo miRNA upregulation has been attempted by employing viral vectors, however, care must be exercised, similar to other viral-based in vivo gene therapy efforts. In addition, while some specificity can be attained based on the AAV serotype, further efforts are necessary to increase delivery specificity to the organ of interest alone, or, even to the cell of interest. However, given the relatively short period of time since discovery of miRNAs, the progress appears sufficient to justify optimism regarding developing novel therapeutics based on miRNAs.

Notes

Conflicts of interest

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854. doi: 10.1016/0092-8674(93)90529-Y PubMedCrossRefGoogle Scholar
  2. 2.
    • Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2):215–233. doi: 10.1016/j.cell.2009.01.002 Google Scholar

This paper is an excellent review regarding current understanding of miRNA target recognition and mechanism of action.

  1. 3.
    Faller M, Guo F (2008) MicroRNA biogenesis: there’s more than one way to skin a cat. Biochim Biophys Acta 1779(11):663–667. doi: 10.1016/j.bbagrm.2008.08.005 PubMedCrossRefGoogle Scholar
  2. 4.
    Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ (2004) Processing of primary microRNAs by the Microprocessor complex. Nature 432(7014):231–235. doi: 10.1038/nature03049 PubMedCrossRefGoogle Scholar
  3. 5.
    Yi R, Qin Y, Macara IG, Cullen BR (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17(24):3011–3016. doi: 10.1101/gad.11588031158803 PubMedCrossRefGoogle Scholar
  4. 6.
    Lee YS, Nakahara K, Pham JW, Kim K, He Z, Sontheimer EJ et al (2004) Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 117(1):69–81PubMedCrossRefGoogle Scholar
  5. 7.
    Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110(5):563–574PubMedCrossRefGoogle Scholar
  6. 8.
    van Rooij E, Purcell AL, Levin AA (2012) Developing microRNA therapeutics. Circ Res 110(3):496–507. doi: 10.1161/CIRCRESAHA.111.247916 PubMedCrossRefGoogle Scholar
  7. 9.
    Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH et al (2011) Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 13(1):R2. doi: 10.1186/bcr2803 PubMedCrossRefGoogle Scholar
  8. 10.
    Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D et al (2010) microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 9(6):1031–1036PubMedCrossRefGoogle Scholar
  9. 11.
    Dinger ME, Mercer TR, Mattick JS (2008) RNAs as extracellular signaling molecules. J Mol Endocrinol 40(4):151–159. doi: 10.1677/JME-07-0160 PubMedCrossRefGoogle Scholar
  10. 12.
    Bader AG, Brown D, Stoudemire J, Lammers P (2011) Developing therapeutic microRNAs for cancer. Gene Ther 18(12):1121–1126. doi: 10.1038/gt.2011.79 PubMedCrossRefGoogle Scholar
  11. 13.
    Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8(2):129–138. doi: 10.1038/nrd2742 PubMedCrossRefGoogle Scholar
  12. 14.
    Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N et al (2010) Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18(1):181–187. doi: 10.1038/mt.2009.207 PubMedCrossRefGoogle Scholar
  13. 15.
    Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K et al (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102(34):12177–12182. doi: 10.1073/pnas.0501753102 PubMedCrossRefGoogle Scholar
  14. 16.
    • Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D et al (2011) Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19(6):1116–1122. doi: 10.1038/mt.2011.48 Google Scholar

This paper employs lipid nanoparticles to deliver miRNAs in vivo.

  1. 17.
    Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70(14):5923–5930. doi: 10.1158/0008-5472.CAN-10-0655 PubMedCrossRefGoogle Scholar
  2. 18.
    Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP, Lee LJ (2011) MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm 8(4):1381–1389. doi: 10.1021/mp2002076 PubMedCrossRefGoogle Scholar
  3. 19.
    Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al (2008) The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14(11):1271–1277. doi: 10.1038/nm.1880 PubMedCrossRefGoogle Scholar
  4. 20.
    Miyazaki Y, Adachi H, Katsuno M, Minamiyama M, Jiang YM, Huang Z et al (2012) Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nat Med 18(7):1136–1141. doi: 10.1038/nm.2791 PubMedCrossRefGoogle Scholar
  5. 21.
    Maegdefessel L, Azuma J, Toh R, Deng A, Merk DR, Raiesdana A et al (2012) MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med 4(122):122ra22. doi: 10.1126/scitranslmed.3003441 PubMedCrossRefGoogle Scholar
  6. 22.
    • Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6):1005–1017. doi: 10.1016/j.cell.2009.04.021 Google Scholar

This study describes the successful use of adenoassociated viruses to transduce miRNA in vivo.

  1. 23.
    Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M et al (2010) Regression of murine lung tumors by the let-7 microRNA. Oncogene 29(11):1580–1587. doi: 10.1038/onc.2009.445 PubMedCrossRefGoogle Scholar
  2. 24.
    Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR et al (2007) Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 27(6):2240–2252. doi: 10.1128/MCB.02005-06 PubMedCrossRefGoogle Scholar
  3. 25.
    Czech MP (2006) MicroRNAs as therapeutic targets. N Engl J Med 354(11):1194–1195. doi: 10.1056/NEJMcibr060065 PubMedCrossRefGoogle Scholar
  4. 26.
    Meister G, Landthaler M, Dorsett Y, Tuschl T (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10(3):544–550PubMedCrossRefGoogle Scholar
  5. 27.
    Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438(7068):685–689. doi: 10.1038/nature04303 PubMedCrossRefGoogle Scholar
  6. 28.
    Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ et al (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31(11):2705–2716PubMedCrossRefGoogle Scholar
  7. 29.
    Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M et al (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3(2):87–98. doi: 10.1016/j.cmet.2006.01.005 PubMedCrossRefGoogle Scholar
  8. 30.
    Chiu YL, Rana TM (2003) siRNA function in RNAi: a chemical modification analysis. RNA 9(9):1034–1048PubMedCrossRefGoogle Scholar
  9. 31.
    Davis S, Propp S, Freier SM, Jones LE, Serra MJ, Kinberger G et al (2009) Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 37(1):70–77. doi: 10.1093/nar/gkn904 PubMedCrossRefGoogle Scholar
  10. 32.
    Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S et al (2011) Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 121(7):2921–2931. doi: 10.1172/JCI57275 PubMedCrossRefGoogle Scholar
  11. 33.
    Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M et al (2008) Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3(5):e2236. doi: 10.1371/journal.pone.0002236 PubMedCrossRefGoogle Scholar
  12. 34.
    Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432(7014):173–178. doi: 10.1038/nature03121 PubMedCrossRefGoogle Scholar
  13. 35.
    Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S et al (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452(7189):896–899. doi: 10.1038/nature06783 PubMedCrossRefGoogle Scholar
  14. 36.
    Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C et al (2011) Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43(4):371–378. doi: 10.1038/ng.786 PubMedCrossRefGoogle Scholar
  15. 37.
    Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T et al (2000) Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 97(10):5633–5638PubMedCrossRefGoogle Scholar
  16. 38.
    Good L, Nielsen PE (1998) Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA. Proc Natl Acad Sci USA 95(5):2073–2076PubMedCrossRefGoogle Scholar
  17. 39.
    Fabani MM, Abreu-Goodger C, Williams D, Lyons PA, Torres AG, Smith KG et al (2010) Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res 38(13):4466–4475. doi: 10.1093/nar/gkq160 PubMedCrossRefGoogle Scholar
  18. 40.
    Ebert MS, Sharp PA (2010) MicroRNA sponges: progress and possibilities. RNA 16(11):2043–2050. doi: 10.1261/rna.2414110 PubMedCrossRefGoogle Scholar
  19. 41.
    Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT (2012) Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 11(4):316–322. doi: 10.1038/nmat3253 PubMedCrossRefGoogle Scholar
  20. 42.
    Wang Z (2011) The principles of miRNA-masking antisense oligonucleotides technology. Methods Mol Biol 676:43–49. doi: 10.1007/978-1-60761-863-8_3 PubMedCrossRefGoogle Scholar
  21. 43.
    Marquez RT, McCaffrey AP (2008) Advances in microRNAs: implications for gene therapists. Hum Gene Ther 19(1):27–38. doi: 10.1089/hum.2007.147 PubMedCrossRefGoogle Scholar
  22. 44.
    Singh S, Narang AS, Mahato RI (2011) Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res 28(12):2996–3015. doi: 10.1007/s11095-011-0608-1 PubMedCrossRefGoogle Scholar
  23. 45.
    Wilson PA, Plucinski M (2011) A simple Bayesian estimate of direct RNAi gene regulation events from differential gene expression profiles. BMC Genomics 12:250. doi: 10.1186/1471-2164-12-250 PubMedCrossRefGoogle Scholar
  24. 46.
    Seinen E, Burgerhof JG, Jansen RC, Sibon OC (2010) RNAi experiments in D. melanogaster: solutions to the overlooked problem of off-targets shared by independent dsRNAs. PLoS ONE 5(10):e13119. doi: 10.1371/journal.pone.0013119 PubMedCrossRefGoogle Scholar
  25. 47.
    Yamanaka S, Campbell NR, An F, Kuo SC, Potter JJ, Mezey E et al (2012) Coordinated effects of microRNA-494 induce G(2)/M arrest in human cholangiocarcinoma. Cell Cycle 11(14):2729–2738. doi: 10.4161/cc.21105 PubMedCrossRefGoogle Scholar
  26. 48.
    Bueno MJ, Malumbres M (1812) MicroRNAs and the cell cycle. Biochim Biophys Acta 5:592–601. doi: 10.1016/j.bbadis.2011.02.002 Google Scholar
  27. 49.
    Cho WC (2012) MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets 16(8):747–759. doi: 10.1517/14728222.2012.696102 PubMedCrossRefGoogle Scholar
  28. 50.
    Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2):647–658PubMedCrossRefGoogle Scholar
  29. 51.
    Li Y, Zhu X, Gu J, Hu H, Dong D, Yao J et al (2010) Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 15(4):215–221. doi: 10.1179/102453310X12647083620840 PubMedCrossRefGoogle Scholar
  30. 52.
    Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E et al (2010) Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 18(3):282–293. doi: 10.1016/j.ccr.2010.08.013 PubMedCrossRefGoogle Scholar
  31. 53.
    Yamanaka S, Olaru AV, An F, Luvsanjav D, Jin Z, Agarwal R et al (2012) MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. Dig Liver Dis 44(7):589–596. doi: 10.1016/j.dld.2012.02.016 PubMedCrossRefGoogle Scholar
  32. 54.
    Steele CW, Oien KA, McKay CJ, Jamieson NB (2011) Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas 40(8):1165–1171. doi: 10.1097/MPA.0b013e3182218ffb00006676-201111000-00002 PubMedCrossRefGoogle Scholar
  33. 55.
    Wong ST, Zhang XQ, Zhuang JT, Chan HL, Li CH, Leung GK (2012) MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res 32(7):2835–2841PubMedGoogle Scholar
  34. 56.
    Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K (2007) MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 67(19):8994–9000. doi: 10.1158/0008-5472.CAN-07-1045 PubMedCrossRefGoogle Scholar
  35. 57.
    Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S et al (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361(15):1437–1447. doi: 10.1056/NEJMoa0901282 PubMedCrossRefGoogle Scholar
  36. 58.
    Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD (2010) Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci USA 107(5):2183–2188. doi: 10.1073/pnas.0909896107 PubMedCrossRefGoogle Scholar
  37. 59.
    Zhang J, Han C, Wu T (2012) MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin. Gastroenterology 143(1):246–256e8. doi: 10.1053/j.gastro.2012.03.045 Google Scholar
  38. 60.
    Lee CT, Risom T, Strauss WM (2007) Evolutionary conservation of microRNA regulatory circuits: an examination of microRNA gene complexity and conserved microRNA-target interactions through metazoan phylogeny. DNA Cell Biol 26(4):209–218. doi: 10.1089/dna.2006.0545 PubMedCrossRefGoogle Scholar
  39. 61.
    Shi XB, Tepper CG, deVere White RW (2008) Cancerous miRNAs and their regulation. Cell Cycle 7(11):1529–1538PubMedCrossRefGoogle Scholar
  40. 62.
    Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6(4):259–269. doi: 10.1038/nrc1840 PubMedCrossRefGoogle Scholar
  41. 63.
    Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X et al (2012) MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem 287(2):1527–1537. doi: 10.1074/jbc.M111.278705 PubMedCrossRefGoogle Scholar
  42. 64.
    Barh D, Malhotra R, Ravi B, Sindhurani P (2010) MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol 17(1):70–80PubMedCrossRefGoogle Scholar
  43. 65.
    Dong Q, Meng P, Wang T, Qin W, Wang F, Yuan J et al (2010) MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One 5(4):e10147. doi: 10.1371/journal.pone.0010147 PubMedCrossRefGoogle Scholar
  44. 66.
    Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L et al (2008) The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7(6):759–764PubMedCrossRefGoogle Scholar
  45. 67.
    Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA et al (2008) Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA. 105(10):3903–3908. doi: 10.1073/pnas.0712321105 PubMedCrossRefGoogle Scholar
  46. 68.
    Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309(5740):1577–1581. doi: 10.1126/science.1113329 PubMedCrossRefGoogle Scholar
  47. 69.
    • Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME et al (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962):198-201. doi: 10.1126/science.1178178 Google Scholar

This study, along with Reference 68, formed the basis for anti-Hepatitis C miRNA-122-based therapeutics, including the first Phase II clinical studies in humans to employ miRNA based therapeutics.

  1. 70.
    Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W (2009) Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 15(1):31–33. doi: 10.1038/nm.1902 PubMedCrossRefGoogle Scholar
  2. 71.
    Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W et al (2006) Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 99(3):671–678. doi: 10.1002/jcb.20982 PubMedCrossRefGoogle Scholar
  3. 72.
    Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q et al (2012) MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/beta-catenin pathway. Liver Int 32(5):752–760. doi: 10.1111/j.1478-3231.2011.02750.x PubMedCrossRefGoogle Scholar
  4. 73.
    Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R et al (2012) MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122(8):2884–2897. doi: 10.1172/JCI63455 PubMedCrossRefGoogle Scholar
  5. 74.
    Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H et al (2012) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122(8):2871–2883. doi: 10.1172/JCI63539 PubMedCrossRefGoogle Scholar
  6. 75.
    Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ et al (2010) miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 207(8):1589–1597. doi: 10.1084/jem.20100035 PubMedCrossRefGoogle Scholar
  7. 76.
    • Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M et al (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456(7224):980–984. doi: 10.1038/nature07511 Google Scholar

This study clarifies the involvement of miRNA-21 in fibrosis, with particular emphasis on heart fibrosis and failure.

  1. 77.
    • Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE et al (2010) MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328(5985):1566-1569. doi: 10.1126/science.1189123 Google Scholar

This paper reveals the cooperation between miRNA-33 and its mother gene in regulating lipid metabolism.

  1. 78.
    Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, Tzeng CR et al (2011) miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res 13(6):R116. doi: 10.1186/bcr3059 PubMedCrossRefGoogle Scholar
  2. 79.
    Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y et al (2012) MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One 7(1):e29750. doi: 10.1371/journal.pone.0029750PONE-D-11-19620 PubMedCrossRefGoogle Scholar
  3. 80.
    Thomas M, Lange-Grunweller K, Weirauch U, Gutsch D, Aigner A, Grunweller A et al (2012) The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 31(7):918–928. doi: 10.1038/onc.2011.278 PubMedCrossRefGoogle Scholar
  4. 81.
    Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal R, Mori Y et al (2011) MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene 30(13):1577–1585. doi: 10.1038/onc.2010.534 PubMedCrossRefGoogle Scholar
  5. 82.
    Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F et al (2011) MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 17(9):2725–2733. doi: 10.1158/1078-0432.CCR-10-2132 PubMedCrossRefGoogle Scholar
  6. 83.
    Kwak HJ, Kim YJ, Chun KR, Woo YM, Park SJ, Jeong JA et al (2011) Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 30(21):2433–2442. doi: 10.1038/onc.2010.620 PubMedCrossRefGoogle Scholar
  7. 84.
    Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW et al (2012) MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene 31(1):80–92. doi: 10.1038/onc.2011.208 PubMedCrossRefGoogle Scholar
  8. 85.
    Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y et al (2010) MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 120(4):1298–1309. doi: 10.1172/JCI39566 PubMedCrossRefGoogle Scholar
  9. 86.
    Zhang JG, Guo JF, Liu DL, Liu Q, Wang JJ (2011) MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol 6(4):671–678. doi: 10.1097/JTO.0b013e318208eb35 PubMedCrossRefGoogle Scholar
  10. 87.
    Lou Y, Yang X, Wang F, Cui Z, Huang Y (2010) MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int J Mol Med 26(6):819–827PubMedCrossRefGoogle Scholar
  11. 88.
    Wendler A, Keller D, Albrecht C, Peluso JJ, Wehling M (2011) Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. Oncol Rep 25(1):273–279PubMedGoogle Scholar
  12. 89.
    Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E et al (2010) MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70(11):4528–4538. doi: 10.1158/0008-5472.CAN-09-4467 PubMedCrossRefGoogle Scholar
  13. 90.
    Srivastava SK, Bhardwaj A, Singh S, Arora S, Wang B, Grizzle WE et al (2011) MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis 32(12):1832–1839. doi: 10.1093/carcin/bgr223 PubMedCrossRefGoogle Scholar
  14. 91.
    Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Janne OA et al (2012) Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 31(41):4460–4471. doi: 10.1038/onc.2011.624 PubMedCrossRefGoogle Scholar
  15. 92.
    Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17(2):211–215. doi: 10.1038/nm.2284 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologySchool of Medicine, Johns Hopkins UniversityBaltimoreUSA
  2. 2.Division of Hepato-Biliary Pancreatic SurgeryTohoku University Graduate School of MedicineSendaiJapan

Personalised recommendations